Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 101–200 of 1,002
The endocannabinoid system in brain reward processes
Solinas, M., Goldberg, S. R., & Piomelli, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.130 · Cited by 244
“However, these effects were obtained at doses of URB597 3–10 times higher than those required to produce significant inhibition of FAAH (Kathuria et al., 2003) and dramatic potentiation of the effects of exogenously administered anandamide (Solinas et al., 2006a, 2007b) and, thus, the…”
BackgroundInfluentialSelf-citationHill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 239
“Moreover, genetic deletion of FAAH decreases anxiety-like behaviors via a CB1-dependent mechanism (Kathuria et al, 2003; Moreira et al, 2008).”
BackgroundCorticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
Gray, J. M., Vecchiarelli, H. A., Morena, M., Lee, T. T. Y., Hermanson, D. J., Kim, A. B., McLaughlin, R. J., Hassan, K. I., Kühne, C., Wotjak, C. T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2737-14.2015 · Cited by 246
“…are both found in stress-regulating structures and exert well-documented opposing roles on stress- and anxiety-like behavior (Timpl et al., 1998; Kathuria et al., 2003), few studies have investigated whether these systems exhibit any functional interactions (Bayatti et al., 2005; Kamprath et…”
BackgroundThe psychiatric side-effects of rimonabant
Moreira, F. A., & Crippa, J. A. S. (2009) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462009000200012 · Cited by 235
Click-generated triazole ureas as ultrapotent in vivo–active serine hydrolase inhibitors
Adibekian, A., Martin, B. R., Wang, C., Hsu, K.-L., Bachovchin, D. A., Niessen, S., Hoover, H., & Cravatt, B. F. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.579 · Cited by 243
“We therefore selected the pyrrolidine- and morpholine-based scaffolds of AA26-8 (15) and AA26-5 (12) as starting points for constructing a focused library of 1,2,3-triazole ureas, where we hypothesized that introducing substituents onto the triazole group would enhance selectivity for individual SHs.”
BackgroundMethodInfluentialFood Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small Intestine
Fu, J., Astarita, G., Gaetani, S., Kim, J., Cravatt, B. F., Mackie, K., & Piomelli, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607809200 · Cited by 244
Self-citationReich, C. G., Taylor, M. E., & McCarthy, M. M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.013 · Cited by 244
“Inhibiting the breakdown of AEA by the enzyme fatty acid amide hydrolase (FAAH) also produces anxiolytic responses [12] presumably by increasing endogenous AEA.”
BackgroundMetabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways
Ueda, N., Tsuboi, K., & Uyama, T. (2013) · The FEBS Journal · doi:10.1111/febs.12152 · Cited by 234
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
Peripheral gating of pain signals by endogenous lipid mediators
Piomelli, D., & Sasso, O. (2014) · Nature Neuroscience · doi:10.1038/nn.3612 · Cited by 246
Self-citationInhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus
Kim, J., & Alger, B. E. (2004) · Nature Neuroscience · doi:10.1038/nn1262 · Cited by 238
Ferber, S. G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., Shbiro, L., & Weller, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x17666190903103923 · Cited by 227
Chanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P., Piesla, M. J., Zhang, M.-Y., Bingham, B., Uveges, A., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068304 · Cited by 226
“Pharmacological inhibition of FAAH using selective inhibitors was shown to elevate AEA levels throughout the nervous system and periphery (Cravatt et al., 2001; Kathuria et al., 2003; Lichtman et al., 2004).”
MethodAnxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404
Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G. L., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301061 · Cited by 231
“After internalization, anandamide is hydrolyzed by fatty-acid amide hydrolase (FAAH) (Désarnaud et al, 1995; Hillard et al, 1995; Ueda et al, 1995; Cravatt et al, 1996), an intracellular membrane-bound enzyme whose activity is selectively blocked by the compounds cyclohexylcarbamic acid 30-carbamoylbiphenyl-3-yl este…”
BackgroundInfluentialSelf-citationSelective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus
Makara, J. K., Mor, M., Fegley, D., Szabó, S. I., Kathuria, S., Astarita, G., Duranti, A., Tontini, A., Tarzia, G., Rivara, S., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1521 · Cited by 232
Self-citationSolinas, M., Justinova, Z., Goldberg, S. R., & Tanda, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03880.x · Cited by 228
“In our study, the administration of the FAAH inhibitor URB597 (Kathuria et al. 2003) dramatically potentiated both the magnitude and the duration of the anandamide-induced increases in DA levels sensitive to CB1 receptor blockade, resulting in increases in DA levels similar in duration to those produced by its metabol…”
BackgroundInfluentialDinh, T. P., Kathuria, S., & Piomelli, D. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.002071 · Cited by 229
“Pharmacological blockade of FAAH activity or deletion of the faah gene markedly decreases anandamide degradation in the rodent central nervous system (Cravatt et al., 2001; Kathuria et al., 2003).”
Self-citationThe endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
“Following the characterization of the first relatively selective FAAH inhibitor, URB597, Piomelli’s group established over a decade ago that inhibition of AEA hydrolysis produces anxiolytic-like effects in rats (Kathuria et al., 2003).”
BackgroundThe endocannabinoid system: emotion, learning and addiction
Moreira, F. A., & Lutz, B. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00104.x · Cited by 222
“1991), compounds that enhance the endogenous levels of endocannabinoids do not tend to modify locomotion (Kathuria et al. 2003).”
BackgroundInfluentialHill, M. N., & Gorzalka, B. B. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.03.003 · Cited by 231
“Furthermore, the apparent anxiolytic properties elicited by FAAH inhibition (Kathuria et al., 2003) also suggest that this avenue is advantageous because of the potential to treat both anxiety and depression.”
BackgroundResultSimon, G. M., & Cravatt, B. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707807200 · Cited by 228
Ahn, K., Smith, S. E., Liimatta, M. B., Beidler, D., Sadagopan, N., Dudley, D. T., Young, T., Wren, P., Zhang, Y., Swaney, S., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180257 · Cited by 230
“…et al., 2001; Kathuria et al., 2003; Lichtman et al., 2004; Chang et al., 2006; Jayamanne et al., 2006; Russo et al., 2007; Ahn et al., 2009; Kinsey et al., 2009; Naidu et al., 2010), anti-inflammation (Cravatt et al., 2004; Massa et al., 2004; Holt et al., 2005), anxiolysis (Kathuria et…”
BackgroundFegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230
Self-citationJekyll and Hyde: Two Faces of Cannabinoid Signaling in Male and Female Fertility
Wang, H., Dey, S. K., & Maccarrone, M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0006 · Cited by 232
“In addition, the development and use of FAAH activators calls for attention to “the other side of the coin,” because there is effort to develop FAAH inhibitors (rather than activators) as novel therapeutic agents for the treatment of pain (226), neurodegenerative disorders (111), cancer (244, 245), and anxiety (246).”
Ronesi, J., Gerdeman, G. L., & Lovinger, D. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5214-03.2004 · Cited by 228
“Similarly, in primary cortical neuronal cultures, selective inhibitors of FAAH blocked AEA breakdown without affecting uptake via the AMT (Kathuria et al., 2003).”
BackgroundAlexander, J. P., & Cravatt, B. F. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.011 · Cited by 225
“Characterization of the Mechanism of FAAH Inhibition by Carbamates Several carbamate inhibitors of FAAH have been described in both the scientific [20] and patent [29] literature.”
BackgroundInfluentialFunctional disassociation of the central and peripheral fatty acid amide signaling systems
Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., & Lichtman, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401292101 · Cited by 225
Self-administration of ?9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys
Justinova, Z., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1484-0 · Cited by 220
“Also, self-administration of cannabinoids may have been maintained due to their known analgesic activity resulting in reductions in levels of pain or stress (Martin and Lichtman 1998; Kathuria et al. 2003) produced by restraint, rather than to direct positive reinforcement effects.”
Background2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain
Baggelaar, M. P., Maccarrone, M., & van der Stelt, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.05.002 · Cited by 224
Endocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C. T., & Drago, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 223
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia
Mallet, C., Daulhac, L., Bonnefont, J., Ledent, C., Etienne, M., Chapuy, E., Libert, F., & Eschalier, A. (2008) · Pain · doi:10.1016/j.pain.2008.03.030 · Cited by 223
“[25] and Compton and Martin [7], respectively.”
BackgroundSolorzano, C., Zhu, C., Battista, N., Astarita, G., Lodola, A., Rivara, S., Mor, M., Russo, R., Maccarrone, M., Antonietti, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907417106 · Cited by 223
“Although the enzyme was insensitive to most agents—including the FAAH inhibitor URB597 (Fig.”
BackgroundMethodInfluentialSelf-citationDAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses
Hsu, K.-L., Tsuboi, K., Adibekian, A., Pugh, H., Masuda, K., & Cravatt, B. F. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1105 · Cited by 222
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G., Fowler, C. J., & Hohmann, A. G. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 218
“Importantly, FAAH inhibitors do not produce behaviors associated with a central activation of CB 1 receptors (Kathuria et al., 2003; Jayamanne et al., 2006) and do not appear to behave like THC in drug-discrimination tests (Gobbi et al., 2005), although there may be some issues with respect to…”
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.003 · Cited by 218
Endocannabinoid signaling mediates oxytocin-driven social reward
Wei, D., Lee, D., Cox, C. D., Karsten, C. A., Peñagarikano, O., Geschwind, D. H., Gall, C. M., & Piomelli, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509795112 · Cited by 218
“Confirming FAAH’s role and ruling out developmental compensation as a possible confounder, we noted that single systemic injections of the FAAH inhibitor URB597 (20) during the socialization phase of the test (Fig.”
BackgroundInfluentialSelf-citationBoger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H., Hwang, I., Hedrick, M. P., Leung, D., Acevedo, O., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049614v · Cited by 214
Pertwee, R. G. (2005) · The AAPS Journal · doi:10.1208/aapsj070364 · Cited by 203
Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity
Ahn, K., Johnson, D. S., Fitzgerald, L. R., Liimatta, M., Arendse, A., Stevenson, T., Lund, E. T., Nugent, R. A., Nomanbhoy, T. K., Alexander, J. P., et al. (2007) · Biochemistry · doi:10.1021/bi701378g · Cited by 216
“597 (8), are particularly efficacious in vivo, displaying activity in rodent models of inflammatory ( 12, 18) and neuropathic pain ( 13) as well as anxiety and depression ( 8, 14, 15).”
InfluentialEndocannabinoid mechanisms of pain modulation
Hohmann, A. G., & Suplita, R. L. (2006) · The AAPS Journal · doi:10.1208/aapsj080479 · Cited by 212
A FAAH-Regulated Class of N-Acyl Taurines That Activates TRP Ion Channels
Saghatelian, A., McKinney, M. K., Bandell, M., Patapoutian, A., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi0608008 · Cited by 212
“The genetic ( 8) or chemical ( 9) inactivation of FAAH leads to elevated endogenous levels of fatty acid amides and concomitant analgesic ( 10, 11), anxiolytic (9), anti-depressant ( 12), sleep-enhancing ( 13), and anti-inflammatory (10, 14, 15) phenotypes, promoting FAAH as a potential therapeutic target for a range…”
Mayo, L. M., Asratian, A., Lindé, J., Morena, M., Haataja, R., Hammar, V., Augier, G., Hill, M. N., & Heilig, M. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.034 · Cited by 207
The Role of the Endocannabinoid System in Pain
Woodhams, S. G., Sagar, D. R., Burston, J. J., & Chapman, V. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-46450-2_7 · Cited by 202
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
“The system has thus been hypothesized to be involved in the pathophysiology of SCZ (Emrich, Leweke & Schneider 1997), anxiety (Kathuria et al. 2003) and affective disorders (Ashton et al.”
BackgroundInfluentialMicale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., & Di Marzo, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.98 · Cited by 207
“URB597 (0.1–1 mg/kg per day) also exerted an anxiolytic effect, but only at the highest dose tested (po0.”
InfluentialMitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207
“Indeed, selective FAAH inhibitors have already been developed (Kathuria et al., 2003), and demonstrated to ameliorate neuropathic pain symptoms (Lichtman et al.”
BackgroundCota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205
Depolarization‐induced suppression of excitation in murine autaptic hippocampal neurones
Straiker, A., & Mackie, K. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.091918 · Cited by 201
“Fatty acid amidohydrolase (FAAH) is thought to be responsible for the in vivo breakdown of AEA (and not 2-AG; Kathuria et al. 2003; Lichtman et al. 2004).”
BackgroundLong-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures
Chen, K., Ratzliff, A., Hilgenberg, L., Gulyás, A., Freund, T. F., Smith, M., Dinh, T. P., Piomelli, D., Mackie, K., & Soltesz, I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00499-9 · Cited by 204
“Statistical analyses (most often a t test) were performed with SigmaPlot or SPSS, with a level of 2002; Kathuria et al., 2003).”
MethodSelf-citationAhn, K., Johnson, D. S., & Cravatt, B. F. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903018857 · Cited by 194
“analgesia [11-15], anti-inflammation [16-18], anxiolysis [12,19,20] and antidepression [19,21] without disruptions in motility, cognition or body temperature [11,12,22,23].”
BackgroundResultInfluentialThe endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203
“Similarly, Kathuria and colleagues generated a distinct series of potent carbamate inhibitors of FAAH that, when administered to mice, caused: (1) significant elevations in the brain levels of anandamide, and (2) CB1dependent antinociception in the hot-plate test (Kathuria et al., 2003).”
BackgroundInfluentialDrug discovery considerations in the development of covalent inhibitors
Mah, R., Thomas, J. R., & Shafer, C. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 193
Cannabinoids and Pain: Sites and Mechanisms of Action
Starowicz, K., & Finn, D. P. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.05.003 · Cited by 193
“It has been demonstrated that blocking AEA degradation results in antinociceptive effects in the mouse hotplate test (Kathuria et al., 2003).”
BackgroundChiang, K. P., Niessen, S., Saghatelian, A., & Cravatt, B. F. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.08.008 · Cited by 201
Maione, S., De Petrocellis, L., de Novellis, V, Moriello, A. S., Petrosino, S., Palazzo, E., Rossi, F. S., Woodward, D. F., & Di Marzo, V (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707145 · Cited by 196
“Inhibits some other lipases 0.3–3 mg kg 1, i.p. in mice 1.2–4 nmol, intra PAG, in rats (Kathuria et al., 2003; Lichtmann et al., 2004a; Maione et al., 2006; authors’ unpublished results) OL-135 2.1 nM 410 mM 410 mM No activity up to 10 mM None 1–30 mg kg 1, i.p. in mice (Lichtmann et al., 2004a;…”
BackgroundInfluentialCellular accumulation of anandamide: consensus and controversy
Hillard, C. J., & Jarrahian, A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705468 · Cited by 203
“Finally, FAAH inhibitors do not reduce the accumulation of AEA in astrocytes (Beltramo et al., 1997) or cortical neurons (Kathuria et al., 2003) in spite of the fact that these cells have FAAH activity.”
BackgroundInhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
Roques, B. P., Fournié-Zaluski, M.-C., & Wurm, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3673 · Cited by 194
Chang, J. W., Niphakis, M. J., Lum, K. M., Cognetta, A. B., Wang, C., Matthews, M. L., Niessen, S., Buczynski, M. W., Parsons, L. H., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.009 · Cited by 193
“FAAH(!/!) mice or rodents treated with FAAH inhibitors, for instance, show antihyperalgesia and antianxiety/depression without exhibiting psychotropic responses or deficits in motor function (Cravatt et al., 2001; Lichtman et al., 2004; Kathuria et al., 2003; Ahn et al., 2009).”
BackgroundInfluentialHill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 192
“sponses in the isolation-induced vocalization paradigm and the elevated zero-maze (Kathuria et al., 2003).”
BackgroundLutz, B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.007 · Cited by 192
Morgese, M. G., Cassano, T., Cuomo, V., & Giuffrida, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.021 · Cited by 196
“As previously reported (Kathuria et al., 2003), URB597 did not increase 2-AG levels in either animal group.”
BackgroundSelf-citationEndocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats
Trezza, V., Damsteegt, R., Manduca, A., Petrosino, S., Van Kerkhof, L. W. M., Pasterkamp, R. J., Zhou, Y., Campolongo, P., Cuomo, V., Di Marzo, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0114-12.2012 · Cited by 190
“The indirect cannabinoid agonist URB597 (Cayman Chemical), which inhibits fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (Kathuria et al., 2003), and the CB1 cannabinoid receptor antagonist/ inverse agonist SR141716A (National Institute of Mental Health’s Chemical Synthesis…”
InfluentialSelf-citationEndocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 180
“…withdrawal tests and the isolation-induced ultrasonic emission test in pups (Bortolato et al., 2006; Braida et al., 2007; Haller et al., 2009; Kathuria et al., 2003; Micale et al., 2009; Moise et al., 2008; Moreira et al., 2008; Naderi et al., 2008; Naidu et al., 2007; Patel et al., 2006;…”
BackgroundMaione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01063.x · Cited by 175
“Clearly, CBD is a much less potent FAAH inhibitor than URB597 (Bisogno et al., 2001; Kathuria et al., 2003), thus possibly explaining why this compound, in terms of its differential effect on the levels of the two endocannabinoids, seemed to be acting in this study more as a weak endocannabinoid…”
BackgroundInfluentialEvaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184
“…the FAAH (−/−) mice (Cravatt et al. 2001; Lichtman et al. 2004b; Varvel et al. 2006) nor the FAAH inhibitor-treated animals (Gobbi et al. 2005; Kathuria et al. 2003; Varvel et al. 2006) exhibit apparent motor alterations, Δ9-THC-like subjective effects, or impaired cognition, which are…”
BackgroundResultInfluentialGoods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Self-citationRusso, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119941 · Cited by 182
“In particular, URB597 reduces pain behaviors in the hot-plate model of thermal nociception (Kathuria et al., 2003) and the adjuvant model of inflammatory pain (Jayamanne et al.”
BackgroundInfluentialSelf-citationThe endocannabinoid system in targeting inflammatory neurodegenerative diseases
Centonze, D., Finazzi-Agrò, A., Bernardi, G., & Maccarrone, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.004 · Cited by 182
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors
Seierstad, M., & Breitenbucher, J. G. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800311k · Cited by 179
Varvel, S. A., Wise, L. E., Niyuhire, F., Cravatt, B. F., & Lichtman, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301224 · Cited by 173
“…et al, 2001), drug dependence (Ledent et al, 1999; Lichtman et al, 2001; Gonzalez et al, 2002), excitotoxicity (Marsicano et al, 2003), anxiety (Kathuria et al, 2003), depression (Gobbi et al, 2005; Witkin et al, 2005), and cognition (Terranova et al, 1996; Marsicano et al, 2002; Varvel et al,…”
BackgroundMethodIgnatowska-Jankowska, B. M., Baillie, G. L., Kinsey, S., Crowe, M., Ghosh, S., Owens, R. A., Damaj, I. M., Poklis, J., Wiley, J. L., Zanda, M., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.148 · Cited by 177
“In contrast, FAAH and MAGL inhibitors produce increased brain levels of AEA (Kathuria et al, 2003) and 2-AG (Long et al, 2009a), respectively.”
BackgroundMoreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
A catalytically silent FAAH-1 variant drives anandamide transport in neurons
Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., Guijarro, A., Lodola, A., Armirotti, A., Garau, G., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.2986 · Cited by 175
Self-citationStructural Basis for Human Monoglyceride Lipase Inhibition
Bertrand, T., Augé, F., Houtmann, J., Rak, A., Vallée, F., Mikol, V., Berne, P. F., Michot, N., Cheuret, D., Hoornaert, C., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.11.060 · Cited by 168
Mayo, L. M., Asratian, A., Lindé, J., Holm, L., Nätt, D., Augier, G., Stensson, N., Vecchiarelli, H. A., Balsevich, G., Aukema, R. J., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0215-1 · Cited by 166
Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells
Muccioli, G. G., Xu, C., Odah, E., Cudaback, E., Cisneros, J. A., Lambert, D. M., López Rodríguez, M. L., Bajjalieh, S., & Stella, N. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4830-06.2007 · Cited by 172
“…signs of anxiety and depression in mice undergoing distress and reduces inflammation-induced pain and autoimmune-mediated cell damage, without inducing CB1 (cannabinoid 1 receptor)-mediated adverse effects (Baker et al., 2001; Kathuria et al., 2003; Cravatt et al., 2004; Gobbi et al., 2005).”
Pharmacological treatments that facilitate extinction of fear: Relevance to psychotherapy
Davis, M., Myers, K. M., Chhatwal, J., & Ressler, K. J. (2006) · NeuroRX · doi:10.1016/j.nurx.2005.12.008 · Cited by 174
“many common mental illnesses, including anxiety disorders, depression, and drug addiction.(49,50) Indeed, the po-”
BackgroundThe future of endocannabinoid-oriented clinical research after CB1 antagonists
Le Foll, B., Gorelick, D. A., & Goldberg, S. R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1506-7 · Cited by 167
“Targeting the enzyme fatty acid amide hydrolase (Gobbi et al. 2005; Kathuria et al. 2003; Scherma et al. 2008a), which breaks down endocannabinoids or the endocannabinoid membrane transporter system (Beltramo et al.”
BackgroundGanon-Elazar, E., & Akirav, I. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1223-09.2009 · Cited by 173
“Indeed, pharmacological augmentation of cannabinoids reduces anxiety-related behavioral responses (Berrendero and Maldonado, 2002; Kathuria et al., 2003) and suppresses restraint stressinduced corticosterone release (Patel et al., 2004).”
BackgroundMelis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yasar, S., Goldberg, S. R., & Pistis, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3221-08.2008 · Cited by 169
“To this aim, the electrophysiological responses of DA neurons to nicotine administration were studied following either blockade of CB1 receptors or, conversely, enhancement of brain endocannabinoid levels by inhibiting fatty acid amide hydrolase (FAAH) (Kathuria et al., 2003; Fegley et al., 2005), the major hydrolyzin…”
BackgroundInfluentialPlant, Synthetic, and Endogenous Cannabinoids in Medicine
Marzo, V. D., & Petrocellis, L. D. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.011205.135648 · Cited by 169
The N‐Acylethanolamine‐Hydrolyzing Acid Amidase (NAAA)
Tsuboi, K., Takezaki, N., & Ueda, N. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790159 · Cited by 172
Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls
Buczynski, M. W., & Parsons, L. H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00787.x · Cited by 158
“Administration of URB597 (0.3 mg·kg-1, i.p.) reduces FAAH activity by over 90% and produces a twofold to fourfold increase in rat and mouse brain AEA content without altering tissue levels of 2-AG (Kathuria et al., 2003; Fegley et al., 2005; Gobbi et al., 2005; Bortolato et al., 2006).”
BackgroundResultInfluentialKinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
“Although irreversible carbamate FAAH inhibitors (e.g., URB597; (Kathuria et al., 2003)) and inhibit FAAH and increase brain levels of anandamide in vivo, they also inhibit other serine hydrolases, calling into question their selectivity for FAAH (Lichtman et al., 2004).”
BackgroundInfluentialAguado, T., Romero, E., Monory, K., Palazuelos, J., Sendtner, M., Marsicano, G., Lutz, B., Guzmán, M., & Galve-Roperh, I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700678200 · Cited by 165
Holt, S., Comelli, F., Costa, B., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706348 · Cited by 168
“These authors demonstrated further that this compound produced potentially important effects in a model of anxiety (the elevated plus maze in the rat) as well as antinociceptive effects in the mouse hotplate test (Kathuria et al., 2003).”
BackgroundInfluentialBilsland, L. G., Dick, J. R. T., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., Greensmith, L., Bilsland, L. G., Dick, J. R. T., Pryce, G., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4743fje · Cited by 164
“Pharmacological inhibition of the Faah enzyme has similarly been shown to have beneficial effects in autoimmune models of inflammation (12, 51), and recently a class of highly selective and reversible Faah inhibitors have been developed, which will further aid research in this field (52).”
BackgroundTargeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation
Schlosburg, J. E., Kinsey, S. G., & Lichtman, A. H. (2009) · The AAPS Journal · doi:10.1208/s12248-008-9075-y · Cited by 165
Genetic Impairment of Frontocortical Endocannabinoid Degradation and High Alcohol Preference
Hansson, A. C., Bermúdez-Silva, F. J., Malinen, H., Hyytiä, P., Sanchez-Vera, I., Rimondini, R., Rodriguez de Fonseca, F., Kunos, G., Sommer, W. H., & Heilig, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301034 · Cited by 163
Endocannabinoids and traumatic brain injury
Shohami, E., Cohen‐Yeshurun, A., Magid, L., Algali, M., & Mechoulam, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01343.x · Cited by 168
Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Mor, M., Rivara, S., Plazzi, P. V., Park, C., Kathuria, S., & Piomelli, D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021119g · Cited by 165
Self-citationSaario, S. M., Savinainen, J. R., Laitinen, J. T., Järvinen, T., & Niemi, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.12.003 · Cited by 163
Ueda, N., Tsuboi, K., & Uyama, T. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.02.003 · Cited by 166
“[199] Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 30-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.”
BackgroundInfluentialJustinova, Z., Mangieri, R. A., Bortolato, M., Chefer, S. I., Mukhin, A. G., Clapper, J. R., King, A. R., Redhi, G. H., Yasar, S., Piomelli, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.008 · Cited by 161
“Our findings further imply that FAAH inhibitors such as URB597 – which have demonstrated analgesic, anxiolytic, antidepressant and antihypertensive properties in rodents (17,18,21,32,33) – may be used in humans without anticipated risk of inducing abuse or provoking relapse to drug use in abstinent individuals.”
InfluentialSelf-citationPatel, S., Cravatt, B. F., & Hillard, C. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300535 · Cited by 164
“URB597 is not soluble in the emulphor vehicle used in all other studies and was therefore delivered in a small volume of DMSO.”
BackgroundMethodInfluentialPan, B., Wang, W., Long, J. Z., Sun, D., Hillard, C. J., Cravatt, B. F., & Liu, Q.-S. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158162 · Cited by 165
“Previous studies have shown that the selective FAAH inhibitor URB597 (Kathuria et al., 2003) amplifies the AEA- induced depression of IPSCs in hippocampal neurons (Kim and Alger, 2004) and cerebellar Purkinje neurons (Szabo et al., 2006).”
BackgroundAnandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities
Mock, E. D., Gagestein, B., & van der Stelt, M. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101194 · Cited by 176
Patel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.